Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Friedman

Showing results (1401-1410 of 1,475) with videos related to

Pageof 148
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 8, 2000
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapyG Akabani, I Cokgor, R E Coleman, et al.
NPJ Parkinson'S Disease|December 17, 2019
Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's diseaseGregory M Pontone, Nadeeka Dissanayka, Liana Apostolova, et al.
NPJ Parkinson'S Disease|June 19, 2020
Erratum: Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's diseaseGregory M Pontone, Nadeeka Dissanayaka, Liana Apostolova, et al.
The New England Journal of Medicine|June 27, 2018
Recurrent Glioblastoma Treated with Recombinant PoliovirusAnnick Desjardins, Matthias Gromeier, James E Herndon, et al.
Plos One|March 3, 2012
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaJohn H Sampson, Robert J Schmittling, Gary E Archer, et al.
British Journal of Cancer|October 6, 2012
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patientsD A Reardon, J E Herndon, K B Peters, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 12, 2018
SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa responseIngrid Faber, Alberto Rolim Muro Martinez, Carlos Roberto Martins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson, Amy B Heimberger, Gary E Archer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted VaccinationKristen A Batich, Elizabeth A Reap, Gary E Archer, et al.
Blood|July 20, 2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humansDuane A Mitchell, Xiuyu Cui, Robert J Schmittling, et al.
Pageof 148

Showing results (1401-1410 of 1,475) with videos related to

Sort By:
Pageof 148
International Journal of Radiation Oncology, Biology, Physics|March 8, 2000
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapyG Akabani, I Cokgor, R E Coleman, et al.
NPJ Parkinson'S Disease|December 17, 2019
Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's diseaseGregory M Pontone, Nadeeka Dissanayka, Liana Apostolova, et al.
NPJ Parkinson'S Disease|June 19, 2020
Erratum: Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's diseaseGregory M Pontone, Nadeeka Dissanayaka, Liana Apostolova, et al.
The New England Journal of Medicine|June 27, 2018
Recurrent Glioblastoma Treated with Recombinant PoliovirusAnnick Desjardins, Matthias Gromeier, James E Herndon, et al.
Plos One|March 3, 2012
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaJohn H Sampson, Robert J Schmittling, Gary E Archer, et al.
British Journal of Cancer|October 6, 2012
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patientsD A Reardon, J E Herndon, K B Peters, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 12, 2018
SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa responseIngrid Faber, Alberto Rolim Muro Martinez, Carlos Roberto Martins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson, Amy B Heimberger, Gary E Archer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted VaccinationKristen A Batich, Elizabeth A Reap, Gary E Archer, et al.
Blood|July 20, 2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humansDuane A Mitchell, Xiuyu Cui, Robert J Schmittling, et al.
Pageof 148